This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese w…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06195306

Phase 2

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05941520